Welcome to the Valproate semisodium (Belvo GR)▼ information page. The materials below have been created to help patients, families, and carers understand the important safety information associated with Valproate. You can view and download the patient information materials by clicking on the links below.
You should visit this page each time you get a new pack to ensure you have the latest information.
For any further information about Valproate semisodium (Belvo GR) you can contact our Medical Information department via email drugsafety@consilienthealth.com or telephone +44 (0)203 751 1888 (option 1).
Valproate semisodium (Belvo GR) ▼
250mg and 500mg Tablets
Belvo gastro-resistant tablet Patient Information Leaflet
Valproate Female Patient Guide GB & NI – May 2025 (aRMM)
Valproate Male Patient Guide GB & NI – May 2025 (aRMM)
Valproate Patient Card GB & NI – May 2025 (aRMM)
Valproate Female ARAF GB & NI – May 2025 (aRMM)
Annual Risk Acknowledgement Form for Female Patients
This form is for female patients aged under 55 years to complete with their specialist. Valproate should only be used in this group when two specialists have confirmed that other treatment options are not suitable. If you are able to become pregnant, you must also meet the requirements of the valproate Pregnancy Prevention Programme (Prevent).
Your specialist should review your treatment regularly and complete this from with you at least once a year. This is to ensure you understand and acknowledge the risks of taking valproate during pregnancy and the importance of avoiding pregnancy while using this medicine.
Valproate Risk Acknowledgement Form for Males GB & NI – May 2025 (aRMM)
Risk Acknowledgement Form For Male Patients
This form is for male patients aged under 55 years to complete with their specialist when starting valproate. Valproate should not be initiated in this group unless two specialists have confirmed that other treatment approaches are unsuitable or that considerations around fertility risk do not apply.
Your specialist should discuss the relevant risks and ensure that the form is completed as part of the initiation process.
Reporting of side effects ▼
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ By reporting side effects, you can help provide more information on the safety of this medicine.
Code No: UK-CH-1790
Date of Preparation: February 2026